Alkem Laboratories Launches Epilepsy Drug NeuCeno

Alkem Laboratories

announced on Wednesday, September 16, 2026, the launch of NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients, marking the drug's first introduction in India. About The Launch The company said an estimated 94 lakh people live with epilepsy in India, giving a sense of the addressable patient population for this therapy. NeuCeno is a once-daily oral treatment, available in strengths ranging from 12.5 mg to 200 mg tablets, allowing dosing to be tailored to individual patients over a titration period, which is typical for anti-seizure medications of this kind. Why This Launch Matters Bringing a novel molecule to market for the first time in a country gives a pharmaceutical company a period of relatively limited direct competition for that specific drug, at least until other companies introduce their own versions or generics become available. For Alkem, expanding into a specialised neurology therapy like this adds to its existing portfolio beyond its traditional strongholds. Business Context Alkem Laboratories is one of India's larger pharmaceutical companies, spanning branded generics, formulations, and active pharmaceutical ingredients, sold domestically and in markets including the United States. Market Backdrop The announcement comes on a day when broader Indian equity benchmarks snapped a two-day losing streak, with the Sensex closing 333 points higher and the Nifty50 up 99 points, driven mainly by gains in banking and financial services stocks. What To Watch Physician adoption rates for NeuCeno in the coming quarters, and how it's priced relative to existing anti-seizure medications available in the Indian market. This update is based on the company's own announcement. It is not investment advice.